Page 119 - 南京医科大学自然科学版第1期
P. 119
第41卷第1期 周本昊,姜 超,韩云宏,等. 经鼻高流量氧疗在基于膈肌浅快呼吸指数评估的高风险脱机
2021年1月 患者中的应用[J]. 南京医科大学学报(自然科学版),2021,41(01):109-113 ·113 ·
phragm dysfunction on admission to the intensive care ratory failure[J]. Am J Respir Crit Care Med,2017,195
unit. Prevalence,risk factors,and prognostic impact⁃a pro⁃ (9):1207-1215
spective study[J]. Am J Respir Crit Care Med,2013,188 [16] VAN HOVE S C,STOREY J,ADAMS C,et al. An experi⁃
(2):213-219 mental and numerical investigation of CO 2 distribution in
[11] SMARGIASSI A,INCHINGOLO R,TAGLIABOSCHI L, the upper airways during nasal high flow therapy[J]. Ann
et al. Ultrasonographic assessment of the diaphragm in Biomed Eng,2016,44(10):3007-3019
chronic obstructive pulmonary disease patients:relation⁃ [17] NISHIMURA M. High⁃flow nasal cannula oxygen therapy
ships with pulmonary function and the influence of body in adults:physiological benefits,indication,clinical bene⁃
composition ⁃ a pilot study[J]. Respiration,2014,87(5): fits,and adverse effects[J]. Respir Care,2016,61(4):
364-371 529-541
[12] ZAMBON M,GRECO M,BOCCHINO S,et al. Assess⁃ [18] XU Z,LI Y,ZHOU J,et al. High⁃flow nasal cannula in
ment of diaphragmatic dysfunction in the critically ill pa⁃ adults with acute respiratory failure and after extubation:
tient with ultrasound:a systematic review[J]. Intensive a systematic review and meta ⁃ analysis[J]. Respir Res,
Care Med,2017,43(1):29-38 2018,19(1):202
[13] LIN C,YU H,FAN H,et al. The efficacy of noninvasive [19] FRAT J P,THILLE A W,MERCAT A,et al. High⁃flow ox⁃
ventilation in managing postextubation respiratory failure: ygen through nasal cannula in acute hypoxemic respirato⁃
a meta⁃analysis[J]. Heart Lung,2014,43(2):99-104 ry failure[J]. N Engl J Med,2015,372(23):2185-
[14] 林炳文,陈名智,肖雄箭,等. 高流量氧疗在ICU机械通 2196
气患者脱机过程中的应用[J]. 中国急救医学,2017,37 [20] 卢 骁,高玉芝,吴春双,等. 经鼻高流量氧疗在基于肺
(9):803-807 超声评估的高风险脱机患者中的应用[J]. 中华急诊医
[15] MAURI T,TURRINI C,ERONIA N,et al. Physiologic ef⁃ 学杂志,2018,27(4):367-372
fects of high⁃flow nasal cannula in acute hypoxemic respi⁃ [收稿日期] 2020-02-12
(上接第81页) [27] LI Q X,SHI D J,ZHANG L X,et al. Association of body
2017,2017(6):1-5 mass and systemic immune⁃inflammation indices with en⁃
[25] MEZQUITA L,AUCLIN E,FERRARA R,et al. Associa⁃ docrine therapy resistance in luminal breast cancers[J]. J
tion of the lung immune prognostic index with immune Int Med Res,2019,47(5):1936-1947
checkpoint inhibitor outcomes in patients with advanced [28] JIANG L,FANG J,DING J. High systemic immune⁃in⁃
non⁃small cell lung cancer[J]. JAMA Oncol,2018,4(3): flammation index predicts poor survival in patients with
351-357 human epidermal growth factor receptor⁃2 positive breast
[26] FRANCO A T,CORKEN A,WARE J. Platelets at the in⁃ cancer receiving adjuvant trastuzumab[J]. Cancer Manag
terface of thrombosis,inflammation,and cancer[J]. Res,2020,12:475-484
Blood,2015,126(5):582-588 [收稿日期] 2020-02-21